Association of a third vaccination with antibody levels and side reactions in essential workers: A prospective cohort study

Hamada, Hiroshi; Futamura, Masaki; Ito, Hiroto; Yamamoto, Ryo; Yata, Kenji; Iwatani, Yoshinori; Inoue, H.; Fukatsu, Noriaki; Nagai, Hirokazu; Hasegawa, Yoshinori

doi:10.1016/j.vaccine.2023.01.050

Cited by 2 publications

(2 citation statements)

References 18 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is limited research on AE after booster COVID-19 vaccination and the relationship with antibody levels. A study from September 2022 on the Comirnaty first booster reported a trend for higher antibodies in the month after vaccination in participants who experienced fever, but this association was not significant [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

Association between adverse events after COVID-19 vaccination and anti-SARS-CoV-2 antibody concentrations, the Netherlands, May 2021 to November 2022: a population-based prospective cohort study

Holwerda,

Hoeve,

Huiberts

et al. 2024

Eurosurveillance

View full text Add to dashboard Cite

Background Non-severe adverse events (AE) including pain at injection site or fever are common after COVID-19 vaccination. Aim To describe determinants of AE after COVID-19 vaccination and investigate the association between AE and pre- and post-vaccination antibody concentrations. Methods Participants of an ongoing prospective cohort study (VASCO) completed a questionnaire on AE within 2 months after vaccination and provided 6 monthly serum samples during May 2021–November 2022. Logistic regression analyses were performed to investigate AE determinants after mRNA vaccination, including pre-vaccination Ig antibody concentrations against the SARS-CoV-2 spike protein receptor binding domain. Multivariable linear regression was performed in SARS-CoV-2-naive participants to assess the association between AE and log-transformed antibody concentrations 3–8 weeks after mRNA vaccination. Results We received 47,947 completed AE questionnaires by 28,032 participants. In 42% and 34% of questionnaires, injection site and systemic AE were reported, respectively. In 2.2% of questionnaires, participants sought medical attention. AE were reported more frequently by women, younger participants (< 60 years), participants with medical risk conditions and Spikevax recipients (vs Comirnaty). Higher pre-vaccination antibody concentrations were associated with higher incidence of systemic AE after the second and third dose, but not with injection site AE or AE for which medical attention was sought. Any AE after the third dose was associated with higher post-vaccination antibody concentrations (geometric mean concentration ratio: 1.38; 95% CI: 1.23–1.54). Conclusions Our study suggests that high pre-vaccination antibody levels are associated with AE, and experiencing AE may be a marker for higher antibody response to vaccination.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between adverse events after COVID-19 vaccination and anti-SARS-CoV-2 antibody concentrations, the Netherlands, May 2021 to November 2022: a population-based prospective cohort study

Holwerda,

Hoeve,

Huiberts

et al. 2024

Eurosurveillance

View full text Add to dashboard Cite

show abstract

“…There is limited research on AE after booster COVID-19 vaccination and the relationship with antibody levels. A study from September 2022 on the booster Comirnaty vaccine reported a trend for higher antibodies in the month after vaccination in participants who experienced fever but this association was not significant (26). Although no signification association was found here, the mechanisms in which vaccination induces the immune response are also known to be involved with systemic side-effects, such as fever (6).…”

Section: Discussionmentioning

confidence: 99%

Association between common adverse events after COVID-19 vaccination and anti-SARS-CoV-2 antibody concentrations in a population-based prospective cohort study in the Netherlands

Holwerda,

Hoeve,

Huiberts

et al. 2023

Preprint

View full text Add to dashboard Cite

INTRODUCTION: Adverse events (AE) such as pain at injection site or fever are common after COVID-19 vaccination. We aimed to describe determinants of AE after COVID-19 vaccination and investigate the association between AE and pre- and post-vaccination antibody concentrations. METHODS: Participants of an ongoing prospective cohort study (VASCO) completed a questionnaire on AE within two months after COVID-19 vaccination and provided 6-monthly serum samples. Data from May 2021 to November 2022 were included. Logistic regression analyses were performed to investigate determinants of AE after mRNA vaccination, including pre-vaccination Ig antibody concentrations against the receptor binding domain. Multivariable linear regression was performed in SARS-CoV-2 naive participants to assess the association between AE and log-transformed antibody concentrations 3-8 weeks after mRNA vaccination. RESULTS: 47,947 AE questionnaires were completed by 28,032 participants. In 42% and 34% of questionnaires, injection site and systemic AE were reported, respectively. In 2.2% of questionnaires, participants sought medical attention due to AE. AE were reported significantly more frequently by women, younger participants (<60 years), participants with medical risk conditions and Spikevax recipients (versus Comirnaty). Higher pre-vaccination antibody concentrations were associated with higher incidence of systemic AE after the second and third dose, but not with injection site AE or AE for which medical attention was sought. Any AE after the third dose was associated with higher post-vaccination antibody concentrations (geometric mean concentration ratio: 1.38, 95%CI 1.23-1.54). CONCLUSION: Our study suggests that high pre-vaccination antibody levels induce AE, and that experiencing AE may be a marker for a good antibody response to vaccination.

show abstract

Association of a third vaccination with antibody levels and side reactions in essential workers: A prospective cohort study

Cited by 2 publications

References 18 publications

Association between adverse events after COVID-19 vaccination and anti-SARS-CoV-2 antibody concentrations, the Netherlands, May 2021 to November 2022: a population-based prospective cohort study

Association between adverse events after COVID-19 vaccination and anti-SARS-CoV-2 antibody concentrations, the Netherlands, May 2021 to November 2022: a population-based prospective cohort study

Association between common adverse events after COVID-19 vaccination and anti-SARS-CoV-2 antibody concentrations in a population-based prospective cohort study in the Netherlands

Contact Info

Product

Resources

About